Studying the angiotensin type 2 receptor (AT 2 ) has been problematic in the past because a pharmacological tool for direct, specific in vitro and in vivo stimulation of the receptor has been lacking. Consequently, current knowledge about AT 2 receptor signalling and function had to be obtained by indirect approaches, like studying animals or cells with genetically altered AT 2 receptor expression levels, inhibitory experiments using specific AT 2 receptor antagonists, stimulation with angiotensin II under concomitant angiotensin II type 1 receptor blockade or stimulation with the peptide agonist CGP42112A, which has additional AT 2 receptor antagonistic properties. The recently developed non-peptide AT 2 receptor agonist Compound 21 now, for the first time, allows direct, selective and specific AT 2 receptor stimulation in vitro and in vivo. This new tool will certainly revolutionise AT 2 receptor research, enable many new insights into AT 2 receptor function and may also have the potential to become a future medical drug. This article reviews milestone findings about AT 2 receptor functional properties obtained by 'conventional' experimental approaches within the last 20 years. Moreover, it provides an overview of the first results obtained by direct AT 2 receptor stimulation with Compound 21, comprising effects on alkaline secretion, neurite outgrowth, blood pressure and post-infarct cardiac function.
Introduction
The era of angiotensin type 2 recept o r (AT 2 ) research began in 1989 when coincidentally, but independently, three research groups developed selective receptor ligands which for the first time allowed the distinction between two main angiotensin receptor subtypes, angiotensin II type 1 (AT 1 ) and AT 2 . [1] [2] [3] These first ligands were losartan (at that time termed DUP753 or Ex89) for the AT 1 receptor, and CGP42112A, EXP655, PD123319 and PD123177 for the AT 2 receptor.
The first experiments using these novel ligands concentrated on affinity and localisation studies in various tissues and species. 4, 5 These studies revealed that angiotensin receptors are almost ubiquitously abundant, but that AT 1 receptors and AT 2 receptors are very much unevenly distributed with the AT 1 receptor expressed at a much higher density than the AT 2 receptor in most tissues of the adult organism. [5] [6] [7] However, in the foetal organism, the proportion of AT 1 receptor versus AT 2 receptor is quite the reverse, with the AT 2 receptor dominating. 6, 7 Moreover, in the adult organism, the AT 2 receptor is re-expressed at a high density in the event of tissue damage, such as myocardial infarction, stroke or cutaneous incisional wounds. [7] [8] [9] [10] After a first boost of data about angiotensin receptor subtype localisation, it surprisingly took years until the first data about the physiological function of the AT 2 receptor were published. This delay was due to the fact that nobody expected the AT 2 receptor to mediate actions opposing those mediated by the AT 1 receptor. Rather, it was expected that the known 'classical' actions of angiotensin II could now be assigned to one or the other receptor subtype. But this was not the case. Only in 1995, antiproliferation and shortly after prolongation of neurites were the first physiological actions to be described for the AT 2 receptor. 11, 12 The difficulties in detecting AT 2 receptor-mediated actions The life of scientists dedicated to AT 2 receptor research has not been easy in the past, because for many reasons, the examination and detection of AT 2 receptor-mediated actions are often not as straight forward as for other receptors. First of all, AT 2 receptor expression in the adult healthy organism or in cells in culture is generally very low. 4, 5, 7 As a result a) of this typical expression pattern of angiotensin receptor subtypes and b) of an almost identical affinity of the natural ligand, angiotensin II, for both receptor subtypes, treatment of cells or an organism with angiotensin II typically elicits AT 1 receptor-mediated effects.
This problem can be overcome in cell culture by stimulating cells under concomitant AT 1 receptor blockade -an approach which is hardly applicable to the in vivo situation and only very rarely found in the literature. Even in in vitro experiments, it leads to quite complicated experimental protocols. Therefore, when looking at AT 2 receptor-mediated effects in vivo, researchers have turned to genetically altered animal models either overexpressing or lacking the AT 2 receptor. This modern approach of understanding the physiological function of AT 2 receptors has without any doubt significantly contributed to current knowledge. However, one has to be aware that none of these approaches implements the stimulation of AT 2 receptors. AT 2 receptor-overexpressing animals just have a higher number of AT 2 receptors. Even considering the fact that AT 2 receptors may be constitutively active, 13 this permanent, endogenous activity is certainly much lower than the activity after pharmacological stimulation of the receptor. Studies using AT 2 receptor-knockout mice use an even more indirect approach in that they try to identify actions or properties which cannot be found in AT 2 receptor-deficient compared to wild-type animals -they are rather looking for deficiencies and not for actions. A similar, indirect approach is applied in studies using the AT 2 receptor antagonist PD123319. Moreover, PD123319 itself is problematic at least in vivo, because it lacks selectivity when applied in higher doses. 14 The most direct approach for the study of AT 2 receptor-mediated effects would certainly be stimulation of cells or organisms, respectively, with a specific and selective AT 2 receptor agonist. The peptide ligand CGP42112A represents such an agonist, but has certain shortcomings limiting its suitability in research: a) as a peptide it is rapidly degraded in vivo and b) it has agonistic and antagonistic properties. 11 In 2004, Mathias Alterman and Anders Hallberg's group reported design and synthesis of the first specific and selective, orally active, non-peptide AT 2 receptor agonist, Compound 21 (C21). 15 For the first time, this agonist allows direct in vitro and in vivo stimulation of the AT 2 receptor without affecting the AT 1 receptor.
Results from studies of AT 2 receptormediated actions using 'conventional' experimental approaches Studies using the peptide AT 2 receptor agonist CGP42112A Owing to its chemical and pharmacokinetic properties, the peptide CGP42112A is usually only suitable for in vitro studies. Nevertheless, until recently, CGP42112A was the only AT 2 receptor agonist available, and it contributed significantly to some of the first and still important findings about AT 2 receptor signalling and function. Examples are the first description of an AT 2 receptor-coupled second messenger, which is the activation of protein-phosphatases, 16 or the first detection of a physiological function, antiproliferation. 11 Another important finding by means of AT 2 receptor stimulation with CGP42112A is the AT 2 receptor-mediated stimulatory effect on neurite outgrowth, which is commonly accepted to be a marker for neuronal regeneration. 12,17 AT 2 receptor stimulation was shown later to indeed accelerate neuronal regeneration of the sciatic and optical nerves after injury. 18, 19 Another important feature of AT 2 receptors contributing to their tissue protective property, which was already observed using CGP42112A, is anti-inflammation. Three signalling mechanisms mediating antiinflammation have been defined for the AT 2 receptor: inhibition of JAK/STAT signalling, 20 inhibition of NF-kB, 21 and inhibition of COX2 synthesis 22 -the latter two by means of AT 2 receptor stimulation with CGP42112A. Several other publications deal with the question whether AT 2 receptor stimulation causes vasodilation and blood pressure reduction, but data obtained with CGP42112A are controversial in these aspects. 23, 24 Studies using genetically altered animals The groups of Victor Dzau and Tadashi Inagami were the first to sequence and clone the AT 2 receptor. Making use of this knowledge, they soon after, in 1995, generated the first mouse strains deficient in the AT 2 receptor, which certainly was a breakthrough in AT 2 receptor research. 25, 26 Since the AT 2 receptor is located on the X-chromosome, female AT 2 receptor-knockout (AT 2 receptor-KO) mice can be either homozygous or heterozygous, while male AT 2 receptor-KO have the -/Y genotype. Healthy AT 2 receptor-deficient mice display an almost normal phenotype. 25, 26 However, when AT 2 receptor-KO are exposed to disease models, the outcome in these mice usually differs significantly from wildtype controls. In most cases, loss of the AT 2 receptor in these animals causes a deterioration of pathology. For example, in AT 2 receptor/ ApoE-double-knockout mice fed a high cholesterol diet, the atherosclerotic changes are exaggerated when compared to ApoE-KO, without significant changes in plasma cholesterol level and blood pressure. 27, 28 Similarly, in a stroke model, infarct size is enlarged and neurological deficits worsened in AT 2 receptor-KO. 29 A recent study has shown increased pancreatic fibrosis in AT 2 receptor-deficient animals. 30 Most of the controversy about AT 2 receptor actions has arisen from studies of cardiac hypertrophy, fibrosis and post-infarct cardiac function in AT 2 receptor transgenic animal models. While on the one hand several studies again suggest a beneficial effect of the AT 2 receptor under these pathological conditions, others report unfavourable AT 2 receptor-mediated actions. 31, 32 The majority of current data supports a pro-hypertrophic, but antifibrotic effect of the AT 2 receptor in the heart exposed to pressure overload or angiotensin infusions (see Widdop et al. 31 and Funke-Kaiser et al. 32 for a review). It remains to be seen -but is highly probable -whether the new tool in AT 2 receptor research, C21, will help to clarify these uncertainties about the AT 2 receptor in cardiac hypertrophy.
With respect to post-infarct cardiac function, several studies report either improved post-infarct outcome in AT 2 receptor-overexpressing animals or a deterioration in AT 2 receptor-KO mice. [33] [34] [35] [36] [37] Only Ichihara et al. reported reduced infarct sizes in AT 2 receptor-KO, which, however, did not result in increased mortality. 38 The first data using C21 in a myocardial infarction model support a beneficial effect of the AT 2 receptor. 39 These data are reviewed in more detail in the following section.
First results using the non-peptide AT 2 receptor agonist C21 Up to now, two articles have been published reporting data obtained using C21. 15, 39 The first, published in 2004 by Wan et al., mainly described the design and synthesis of this novel peptidomimetic molecule and was written aiming at a medical chemistry audience. 15 Still, this original description already comprised some functional data about blood pressure modification, outgrowth of neurites in cells of neuronal origin, and duodenal alkaline secretion. In 2008, our group was the first to publish an experimental study which tested treatment with C21 for a certain indication, which was the therapeutic improvement of cardiac function after myocardial infarction. 39 In the following sections, the (patho-)physiological effects of C21 published to date are reviewed and discussed.
Duodenal alkaline secretion
The gut is one of several non-cardiovascular organs (such as pancreas, liver, reproductive organs or skin) for which expression of a complete renin-angiotensin system (RAS) has been described, but since only a few research groups work on these rather 'unconventional' RASexpressing organs, the (patho-)physiological function of the RAS in these tissues is not yet very well defined. Nevertheless, evidence has substantially grown in the meantime that even in these non-cardiovascular organs, the RAS has a significant impact on tissue homeostasis.
Regarding the gut, local RAS expression was described in the late 1980s. 40, 41 In terms of function, the intestinal RAS seems involved in the regulation of sodium secretion, water secretion and alkaline secretion with AT 1 receptors and AT 2 receptors mediating opposing actions. 42, 43 Duodenal alkaline secretion represents an important protective mechanism, in that it plays a major role in the inherent mucosal protection against gastric acid in the upper gut. 43 AT 2 receptor stimulation seems to augment this tissue-protective intestinal mechanism as shown by Johansson et al. using a) the 'classical' approach of treatment with angiotensin II under concomitant AT 1 receptor blockade and b) by stimulation of the AT 2 receptor with the peptide agonist CGP42112A. 43 This observation could be confirmed by systemic (i.v.) or topical application of the non-peptide AT 2 receptor agonist C21 for AT 2 receptor stimulation. 15 The effect of C21 was blocked by co-administration of the specific AT 2 receptor antagonist PD123319 in both experimental protocols, pointing to an AT 2 receptor-specific effect of C21.
For more details, see the review article by Lars Fändriks entitled 'The angiotensin type 2 receptor (AT 2 ) and the gastrointestinal tract' in this issue.
Neurite outgrowth
Accelerated neurite outgrowth is one of the earliest findings regarding AT 2 receptor function. 12 A stimulating effect of angiotensin II on neurite elongation had already been described in 1989. 44 However, since these experiments were performed just before receptor subtype-specific ligands became available to distinguish between AT 1 receptor-mediated and AT 2 receptor-mediated effects, it can only be speculated that the effect the researchers described was AT 2 receptor mediated. In 1996, our group and the group of Nicole Gallo-Payet coincidentally published that angiotensin II-induced neurite outgrowth is due to AT 2 receptor stimulation. 12, 17 Gallo-Payet's group used NG 108-15 cells, a neuroblastoma × glioma hybrid, for their study, while our data were obtained in the PC12W cell line derived from rat pheochromocytoma. Both cell lines express only AT 2 receptors, and no AT 1 receptors. Unlike many other physiological effects attributed to the AT 2 receptor, neurite outgrowth has never been questioned to be really and exclusively AT 2 receptor and not AT 1 receptor mediated. Therefore, it is still one of very few physiological readouts which as reliably as in any way possible indicates an AT 2 receptor-mediated effect. Thus, it is of importance that neurite outgrowth has already been demonstrated to result from C21 treatment. Again, it was our group and the one of Gallo-Payet which in NG 108-15 cells measured a dosedependent increase in length and number of neurites in response to C21 (figure 1). 15 This response could be blocked by the established AT 2 receptor antagonist PD123319, indicating again AT 2 receptor specificity. Inhibition experiments further revealed that cGMP is involved in AT 2 receptor-coupled signalling, resulting in elongation of neurites. 15
Does direct AT 2 receptor stimulation lower blood pressure?
As stated above, it is still controversial whether AT 2 receptor stimulation has any impact on blood pressure regulation. Since this is of course a crucial question within the 'RAS community', one major demand of the first in vivo active AT 2 receptor agonist is certainly to shed light onto this uncertainty. This question has indeed already been addressed in the first description of C21 by Wan et al., which reported a lowering of blood pressure in spontaneously hypertensive rats. 15 However, these experiments were performed in anaesthetised spontaneously hypertensive rats, which is problematic inasmuch as anaesthesia can lead to a profound RAS activation, which makes animals much more susceptible to any pharmacological RAS interference than under 'normal' conditions. Therefore, this observation has to be regarded with some caution. In fact, in several ongoing or published studies involving the in vivo application of C21, data about effects of C21 on blood pressure have been obtained using various methods, and in all cases C21 behaved blood pressure neutral. For example, in our study about the effect of C21 on post-myocardial infarction cardiac performance, blood pressure was recorded by intra-aortic Millar catheter in normotensive Wistar rats after seven days of daily treatment with 0.03 or 0.30 mg/kg bodyweight C21 i.p. 39 While 0.03 and 0.30 mg/kg C21 profoundly improved cardiac function and inhibited markers of inflammation, apoptosis and oxidative stress, no changes in blood pressure by these effective doses were detectable (figure 2). 15 Similar data were generated by telemetric recording in normotensive, healthy C57BL/6 mice treated with 3 mg/kg bodyweight per day C21 by osmotic minipump (figure 2). It may be argued that a reduction of blood pressure by C21 may only occur or be detectable in hypertensive and Paper SAGE Publications 2010 Los Angeles, London, New Delhi and Singapore not in normotensive animals, but even in hypertensive, diabetic spontaneously hypertensive stroke-prone rats, a 12-week daily, chronic treatment with 0.3 mg/kg bodyweight C21 per os (an effective dose with respect to other measured markers in this study) did not show any blood pressure-lowering effect (figure 2). 45 Current data, therefore, support the notion that C21 has no effect on blood pressure. Many more data in various animal models are certainly needed to get a complete picture. In particular, it has to be tested whether AT 2 receptor stimulation by C21 in combination with low-dose, blood pressure-neutral AT 1 receptor blockade unmasks an AT 2 receptor-mediated depressor effect as observed by Li and Widdop for the combination of the peptide AT 2 receptor agonist CGP42112A (1 µg/kg bodyweight per min i.v.) with the AT 1 receptor blocker candesartan (5 µg/kg bodyweight i.v.). 23 Still, current knowledge does rather not suggest AT 2 receptor stimulation to become another antihypertensive therapeutic strategy.
C21 in myocardial infarction
The only published study so far testing the therapeutic potential of AT 2 receptor stimulation by C21 for a specific indication looked at the effect of C21 on cardiac performance after myocardial infarction in rats. 39 Myocardial infarction was induced in normotensive Wistar rats by permanent ligation of the left anterior coronary artery. Twenty-four hours after myocardial infarction, treatment with C21 (0.01, 0.03 or 0.30 mg/kg bodyweight i.p.) or candesartan (0.10 mg/kg bodyweight i.p.) as a reference drug was initiated. C21 significantly improved post-myocardial infarction cardiac function as indicated by numerous improved markers determined by echocardiography or Millar catheter. 39 C21 caused no changes in heart rate or blood pressure. Improved cardiac function was most probably a result of a reduced inflammatory response and of ameliorated remodelling of the infarcted area. Thus, increased expression of cytokines and apoptotic markers within the peri-infarct area was reduced almost to normal levels by C21 treatment ( figure  3 ). Moreover, C21, but not candesartan, was able to significantly reduce scar size seven days after myocardial infarction. Since in this study treatment was initiated not earlier than 24 hours after myocardial infarction (which was for reasons of study design, see Kaschina et al. 39 for details), the reduction in scar size was rather not due to improved survival of ischaemic cells, but more 
Figure 2
Effect of C21 on blood pressure. Presented are blood pressure levels of C21-treated animals compared to control animals in three different experimental settings. 
Perspective
At present, there are certainly more questions than answers regarding AT 2 receptor-mediated physiological and patho-physiological actions and -more importantly -regarding the clinical relevance of AT 2 receptor agonism and potential indications. As reviewed above, published data obtained using the novel non-peptide AT 2 receptor agonist C21 point to cardio-protective, neuroprotective, anti-inflammatory, anti-apoptotic and protective intestinal actions of AT 2 receptor agonism. These data are in concordance with the vast majority of data obtained in the past with 'conventional' methods of studying the AT 2 receptor. However, there have also been reports about unfavourable AT 2 receptor-mediated effects in the past, in particular when genetically altered animals or cells were used. Thus, a major future task of AT 2 receptor research will be to clarify whether AT 2 receptor stimulation can indeed not just be beneficial but also detrimental; and if yes, whether the nature of the response depends on certain conditions, tissues, species or pathologies. C21, being an orally active, non-peptide agonist with high specificity and selectivity for the AT 2 receptor, will certainly become a valuable, experimental tool to answer these questions. Owing to its chemical and pharmacokinetic properties, C21 may also be regarded as the lead molecule for a novel class of drugs, the AT 2 receptor agonists. Consequently, a second major future task will be to clarify whether C21 is suitable for therapeutic use in men, whether it is well tolerated and what may become the most rewarding clinical indications.
Figure 3
Effect of C21 on the expression of the apoptotic marker Fas-ligand. Immunohistochemical staining of the apoptotic marker Fasligand in cardiac cross-sections of sham-operated animals, vehicle-treated, infarcted animals or C21-treated (0.03 mg/kg bodyweight per day), infarcted animals seven days after myocardial infarction (magnification ×20). Note the increase in Fas-ligand protein expression (red stain) after myocardial infarction which is strongly reduced by C21 treatment. C21 = Compound 21.
